| 肖珊珊,张卓尔,杨巧红,李建婷,季湍云.丹酚酸B对肝癌荷瘤小鼠抑瘤作用及对肝纤维化的影响[J].现代生物医学进展英文版,2021,(22):4207-4210. |
| 丹酚酸B对肝癌荷瘤小鼠抑瘤作用及对肝纤维化的影响 |
| Salvianolic Acid B on Tumor-inhibiting Effect of Hepatocarcinoma-bearing Mice and Its Effect on Liver Fibrosis Expression |
| Received:April 07, 2021 Revised:April 30, 2021 |
| DOI：10.13241/j.cnki.pmb.2021.22.002 |
| 中文关键词: 丹酚酸B 肝癌 肝纤维化 天门冬氨酸氨基转移酶 转化生长因子-β1 肝脏系数 |
| 英文关键词: Salvianolic acid B Liver cancer Liver fibrosis Aspartate aminotransferase Transforming growth factor-β1 Liver coefficient |
| 基金项目:广东省中医药局科研项目（20211122） |
|
| Hits: 951 |
| Download times: 534 |
| 中文摘要: |
| 摘要 目的：探讨丹酚酸B(salvianolic acid B，Sal B)对肝癌荷瘤小鼠抑瘤作用及对肝纤维化的影响。方法：将HepG2肝癌细胞株皮下注射于裸鼠左腋下成瘤，将荷瘤小鼠(n=42)随机平分为三组：模型组、Sal B 1组与Sal B 2组。Sal B 1组与Sal B 2组于造模成功当天开始分别给予10 mL/kg/d和15 mL/kg/d丹酚酸B进行灌胃，模型组给予等量生理盐水灌胃，每周 2次，连续 4周。结果：治疗第2周与第4周后，Sal B 1组、Sal B 2组的移植瘤重量均低于模型组(P<0.05)，抑瘤率高于模型组(P<0.05)，Sal B 1组与Sal B 2组对比差异有统计学意义(P<0.05)。Sal B 1组、Sal B 2组肝脏系数与肝脏表面癌结节数目均低于模型组(P<0.05)，Sal B 2组低于Sal B 1组(P<0.05)。Sal B 1组、Sal B 2组血清天门冬氨酸氨基转移酶(Aspartate transaminase，AST)、丙氨酸氨基转移酶(Alanine transaminase，ALT)含量均低于模型组(P<0.05)，Sal B 2组低于Sal B 1组(P<0.05)。Sal B 1组、Sal B 2组肝组织转化生长因子-β1(Transforming growth factor-beta 1，TGF-β1)、Smad3蛋白相对表达水平均低于模型组(P<0.05)，Sal B 2组低于Sal B 1组(P<0.05)。结论：Sal B在肝癌荷瘤小鼠中能发挥抑瘤作用，可抑制血清ALT与AST的释放，其可能是通过TGF-β1/Smad3信号发挥抗肝纤维化-肝癌作用。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the tumor-inhibiting effect of salvianolic acid B(Sal B) on liver cancer tumor-bearing mice and its influence on the expression of liver fibrosis. Methods: Mice bearing liver cancer(n=42) were randomly divided into three groups-model group, Sal B 1 group and Sal B 2 group. Sal B 1 group and Sal B 2 group were separately given 10 mL/kg/d and 15 mL/kg/d salvianolic acid B by gavage on the day of modeling, and the model group were given the same amount of normal saline by gavage twice a week for 4 consecutive weeks. Results: The weight of the transplanted tumors in the Sal B 1 group and Sal B 2 group were lower than that of the model group(P<0.05) in the 2nd and 4th weeks of treatment, and the tumor inhibition rate were higher than that of the model group(P<0.05), and compared the difference between the Sal B 1 group and the Sal B 2 group were also statistically significant (P<0.05). The liver coefficient and the number of liver surface cancer nodules in the Sal B 1 group and Sal B 2 group were lower than the model group(P<0.05) in the second and fourth weeks of treatment, and the Sal B 2 group were also lower than the Sal B 1 group (P<0.05). The serum aspartate transaminase (AST) and alanine transaminase (ALT) levels of the Sal B 1 group and Sal B 2 group were lower than the model in the 2nd and 4th weeks of treatment Group(P<0.05), Sal B 2 group were also lower than Sal B 1 group(P<0.05). The relative expression levels of transforming growth factor-β1 (TGF-β1) and Smad3 protein in liver tissues in the 2nd and 4th weeks of treatment in the Sal B 1 group and Sal B 2 group were lower than those in the model group(P<0.05), the Sal B 2 group were also lower than the Sal B 1 group (P<0.05). Conclusion: The application of salvianolic acid B in hepatocarcinoma-bearing mice can inhibit tumors and inhibit the release of serum ALT and AST, which may be through the TGF-β1/Smad3 signal to play anti-liver fibrosis-liver cancer effect. |
|
View Full Text
View/Add Comment Download reader |
| Close |
